AI assistant
ATOSSA THERAPEUTICS, INC. — Director's Dealing 2018
May 31, 2018
34113_dirs_2018-05-31_6c40b2b9-0f2c-4ef0-834a-38507a1f6135.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: ATOSSA GENETICS INC (ATOS)
CIK: 0001488039
Period of Report: 2018-05-30
Reporting Person: Guse Kyle (CFO, Gen Counsel and Secretary)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2018-05-30 | Series B Convertible Preferred Stock | $3.52 | P | 8 | Acquired | Common Stock (2273) | Direct | |
| 2018-05-30 | Warrants | $4.05 | P | 2272 | Acquired | 2022-05-30 | Common Stock (2272) | Direct |
Footnotes
F1: Each share of Series B Convertible Preferred Stock is convertible into the number of shares of Common Stock equal to the stated value of $1,000 divided by $3.52.
F2: Shares of Series B Convertible Preferred Stock do not expire.
F3: No fractional shares will be issued upon conversion. At its election, the Company will either issue a cash adjustment or round up to the next whole share. The number reflected here assumes rounding up to the next whole share.
F4: Shares of Series B Convertible Preferred Stock and Warrants were issued as part of a unit, with each unit consisting of one share of Series B Convertible Preferred Stock and 284 Warrants.